Reconsidering the Turnaround Times for BRAF V600 Mutation Analysis in Non-Small-Cell Lung Cancer: A Molecular Diagnosis in One Day Is Achievable for Rapid Treatment Choices

Current Oncology - Canada
doi 10.3747/co.26.4779
Full Text
Abstract

Available in full text

Categories
Oncology
Date
Authors
Publisher

MultiMed Inc.

Related search

P3.03-01 BRAF V600 and Non-V600 Mutations in Chinese Lung Cancer

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

TRAF1 Is Critical for Regulating the BRAF/MEK/ERK Pathway in Non-Small Cell Lung Carcinogenesis

Cancer Research
Cancer ResearchOncology
2018English

Gefitinib for the Treatment of Non-Small-Cell Lung Cancer

Expert Opinion on Pharmacotherapy
MedicinePharmacology
2010English

TP53 Mutation Is Associated With a Poor Clinical Outcome for Non-Small Cell Lung Cancer: Evidence From a Meta-Analysis

Molecular and Clinical Oncology
Cancer ResearchOncology
2016English

A Novel Method for Finding Non-Small Cell Lung Cancer Diagnosis Biomarkers

BMC Medical Genomics
Genetics
2013English

Importance of Molecular Features of Non–Small Cell Lung Cancer for Choice of Treatment

American Journal of Pathology
Forensic MedicinePathology
2011English

Myc Is a Metastasis Gene for Non-Small-Cell Lung Cancer

PLoS ONE
Multidisciplinary
2009English

METTL7B Is Required for Cancer Cell Proliferation and Tumorigenesis in Non-Small Cell Lung Cancer

Frontiers in Pharmacology
Pharmacology
2020English

P1.01-043 Molecular Testing for Non-Small Cell Lung Cancer in Latin American

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy